Recent Trends in Drug Development for the Treatment of Adenocarcinoma Breast Cancer: Thiazole, Triazole, and Thiosemicarbazone Analogues as Efficient Scaffolds

Kundu, J.K.; Surh, Y. J. Inflammation: gearing the journey to cancer. Mutat. Res., 2008, 659(1-2), 15-30.
[http://dx.doi.org/10.1016/j.mrrev.2008.03.002] [PMID: 18485806]

Kundu, J.K.; Surh, Y.J. Emerging avenues linking inflammation and cancer. Free Radic. Biol. Med., 2012, 52(9), 2013-2037.
[http://dx.doi.org/10.1016/j.freeradbiomed.2012.02.035] [PMID: 22391222]

Aggarwal, B.B.; Shishodia, S.; Sandur, S.K.; Pandey, M.K.; Sethi, G. Inflammation and cancer: how hot is the link? Biochem. Pharmacol., 2006, 72(11), 1605-1621.
[http://dx.doi.org/10.1016/j.bcp.2006.06.029] [PMID: 16889756]

Mansoori, B.; Mohammadi, A.; Davudian, S.; Shirjang, S.; Baradaran, B. The different mechanisms of cancer drug resistance: A brief review. Adv. Pharm. Bull., 2017, 7(3), 339-348.
[http://dx.doi.org/10.15171/apb.2017.041] [PMID: 29071215]

Balkwill, F.; Mantovani, A. Inflammation and cancer: back to Virchow? Lancet, 2001, 357(9255), 539-545.
[http://dx.doi.org/10.1016/S0140-6736(00)04046-0] [PMID: 11229684]

Balkwill, F.; Charles, K.A.; Mantovani, A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell, 2005, 7(3), 211-217.
[http://dx.doi.org/10.1016/j.ccr.2005.02.013] [PMID: 15766659]

Dou, X.; Tong, P.; Huang, H.; Zellmer, L.; He, Y.; Jia, Q.; Zhang, D.; Peng, J.; Wang, C.; Xu, N.; Liao, D.J. Evidence for immortality and autonomy in animal cancer models is often not provided, which causes confusion on key issues of cancer biology. J. Cancer, 2020, 11(10), 2887-2920.
[http://dx.doi.org/10.7150/jca.41324] [PMID: 32226506]

Fidler, M.M.; Bray, F.; Soerjomataram, I. The global cancer burden and human development: A review. Scand. J. Public Health, 2018, 46(1), 27-36.
[http://dx.doi.org/10.1177/1403494817715400] [PMID: 28669281]

Yusuf, S.W.; Cipolla, C.; Durand, J.B.; Lenihan, D.J. Cancer and cardiovascular disease. Cardiol. Res. Pract., 2011, 2011(1)943748
[PMID: 21904686]

2021.https://www.who.int/health-topics/cancer#tab=tab_1

Clemenceau, A.; Michou, L.; Diorio, C.; Durocher, F. Breast cancer and microcalcifications: An osteoimmunological disorder? Int. J. Mol. Sci., 2020, 21(22), 8613.
[http://dx.doi.org/10.3390/ijms21228613] [PMID: 33203195]

Escala-Garcia, M.; Guo, Q.; Dörk, T.; Canisius, S.; Keeman, R.; Dennis, J.; Beesley, J.; Lecarpentier, J.; Bolla, M.K.; Wang, Q.; Abraham, J.; Andrulis, I.L.; Anton-Culver, H.; Arndt, V.; Auer, P.L.; Beckmann, M.W.; Behrens, S.; Benitez, J.; Bermisheva, M.; Bernstein, L.; Blomqvist, C.; Boeckx, B.; Bojesen, S.E.; Bonanni, B.; Børresen-Dale, A.L.; Brauch, H.; Brenner, H.; Brentnall, A.; Brinton, L.; Broberg, P.; Brock, I.W.; Brucker, S.Y.; Burwinkel, B.; Caldas, C.; Caldés, T.; Campa, D.; Canzian, F.; Carracedo, A.; Carter, B.D.; Castelao, J.E.; Chang-Claude, J.; Chanock, S.J.; Chenevix-Trench, G.; Cheng, T.D.; Chin, S.F.; Clarke, C.L.; Cordina-Duverger, E.; Couch, F.J.; Cox, D.G.; Cox, A.; Cross, S.S.; Czene, K.; Daly, M.B.; Devilee, P.; Dunn, J.A.; Dunning, A.M.; Durcan, L.; Dwek, M.; Earl, H.M.; Ekici, A.B.; Eliassen, A.H.; Ellberg, C.; Engel, C.; Eriksson, M.; Evans, D.G.; Figueroa, J.; Flesch-Janys, D.; Flyger, H.; Gabrielson, M.; Gago-Dominguez, M.; Galle, E.; Gapstur, S.M.; García-Closas, M.; García-Sáenz, J.A.; Gaudet, M.M.; George, A.; Georgoulias, V.; Giles, G.G.; Glendon, G.; Goldgar, D.E.; González-Neira, A.; Alnæs, G.I.G.; Grip, M.; Guénel, P.; Haeberle, L.; Hahnen, E.; Haiman, C.A.; Håkansson, N.; Hall, P.; Hamann, U.; Hankinson, S.; Harkness, E.F.; Harrington, P.A.; Hart, S.N.; Hartikainen, J.M.; Hein, A.; Hillemanns, P.; Hiller, L.; Holleczek, B.; Hollestelle, A.; Hooning, M.J.; Hoover, R.N.; Hopper, J.L.; Howell, A.; Huang, G.; Humphreys, K.; Hunter, D.J.; Janni, W.; John, E.M.; Jones, M.E.; Jukkola-Vuorinen, A.; Jung, A.; Kaaks, R.; Kabisch, M.; Kaczmarek, K.; Kerin, M.J.; Khan, S.; Khusnutdi-nova, E.; Kiiski, J.I.; Kitahara, C.M.; Knight, J.A.; Ko, Y.D.; Koppert, L.B.; Kosma, V.M.; Kraft, P.; Kristensen, V.N.; Krüger, U.; Kühl, T.; Lambrechts, D.; Le Marchand, L.; Lee, E.; Lejbkowicz, F.; Li, L.; Lindblom, A.; Lindström, S.; Linet, M.; Lissowska, J.; Lo, W.Y.; Loibl, S. Lubiński, J.; Lux, M.P.; MacInnis, R.J.; Maierthaler, M.; Maishman, T.; Makalic, E.; Mannermaa, A.; Manoochehri, M.; Man-oukian, S.; Margolin, S.; Martinez, M.E.; Mavroudis, D.; McLean, C.; Meindl, A.; Middha, P.; Miller, N.; Milne, R.L.; Moreno, F.; Mulli-gan, A.M.; Mulot, C.; Nassir, R.; Neuhausen, S.L.; Newman, W.T.; Nielsen, S.F.; Nordestgaard, B.G.; Norman, A.; Olsson, H.; Orr, N.; Pankratz, V.S.; Park-Simon, T.W.; Perez, J.I.A.; Pérez-Barrios, C.; Peterlongo, P.; Petridis, C.; Pinchev, M.; Prajzendanc, K.; Prentice, R.; Presneau, N.; Prokofieva, D.; Pylkäs, K.; Rack, B.; Radice, P.; Ramachandran, D.; Rennert, G.; Rennert, H.S.; Rhenius, V.; Romero, A.; Roylance, R.; Saloustros, E.; Sawyer, E.J.; Schmidt, D.F.; Schmutzler, R.K.; Schneeweiss, A.; Schoemaker, M.J.; Schumacher, F.; Schwentner, L.; Scott, R.J.; Scott, C.; Seynaeve, C.; Shah, M.; Simard, J.; Smeets, A.; Sohn, C.; Southey, M.C.; Swerdlow, A.J.; Talhouk, A.; Tamimi, R.M.; Tapper, W.J.; Teixeira, M.R.; Tengström, M.; Terry, M.B.; Thöne, K.; Tollenaar, R.A.E.M.; Tomlinson, I.; Torres, D.; Truong, T.; Turman, C.; Turnbull, C.; Ulmer, H.U.; Untch, M.; Vachon, C.; van Asperen, C.J.; van den Ouweland, A.M.W.; van Veen, E.M.; Wendt, C.; Whittemore, A.S.; Willett, W.; Winqvist, R.; Wolk, A.; Yang, X.R.; Zhang, Y.; Easton, D.F.; Fasching, P.A.; Nevanlinna, H.; Eccles, D.M.; Pharoah, P.D.P.; Schmidt, M.K. Genome-wide association study of germline variants and breast cancer-specific mortali-ty. Br. J. Cancer, 2019, 120(6), 647-657.
[http://dx.doi.org/10.1038/s41416-019-0393-x] [PMID: 30787463]

Hamdi, Y.; Soucy, P.; Adoue, V.; Michailidou, K.; Canisius, S.; Lemaçon, A.; Droit, A.; Andrulis, I.L.; Anton-Culver, H.; Arndt, V.; Baynes, C.; Blomqvist, C.; Bogdanova, N.V.; Bojesen, S.E.; Bolla, M.K.; Bonanni, B.; Borresen-Dale, A.L.; Brand, J.S.; Brauch, H.; Bren-ner, H.; Broeks, A.; Burwinkel, B.; Chang-Claude, J.; Couch, F.J.; Cox, A.; Cross, S.S.; Czene, K.; Darabi, H.; Dennis, J.; Devilee, P.; Dörk, T.; Dos-Santos-Silva, I.; Eriksson, M.; Fasching, P.A.; Figueroa, J.; Flyger, H.; García-Closas, M.; Giles, G.G.; Goldberg, M.S.; González-Neira, A.; Grenaker-Alnæs, G.; Guénel, P.; Haeberle, L.; Haiman, C.A.; Hamann, U.; Hallberg, E.; Hooning, M.J.; Hopper, J.L.; Jakubow-ska, A.; Jones, M.; Kabisch, M.; Kataja, V.; Lambrechts, D.; Le Marchand, L.; Lindblom, A.; Lubinski, J.; Mannermaa, A.; Maranian, M.; Margolin, S.; Marme, F.; Milne, R.L.; Neuhausen, S.L.; Nevanlinna, H.; Neven, P.; Olswold, C.; Peto, J.; Plaseska-Karanfilska, D.; Pylkäs, K.; Radice, P.; Rudolph, A.; Sawyer, E.J.; Schmidt, M.K.; Shu, X.O.; Southey, M.C.; Swerdlow, A.; Tollenaar, R.A.; Tomlinson, I.; Torres, D.; Truong, T.; Vachon, C.; Van Den Ouweland, A.M.; Wang, Q.; Winqvist, R.; Zheng, W.; Benitez, J.; Chenevix-Trench, G.; Dunning, A.M.; Pharoah, P.D.; Kristensen, V.; Hall, P.; Easton, D.F.; Pastinen, T.; Nord, S.; Simard, J. Association of breast cancer risk with genetic variants showing differential allelic expression: Identification of a novel breast cancer susceptibility locus at 4q21. Oncotarget, 2016, 7(49), 80140-80163.
[http://dx.doi.org/10.18632/oncotarget.12818] [PMID: 27792995]

Picon-Ruiz, M.; Morata-Tarifa, C.; Valle-Goffin, J.J.; Friedman, E.R.; Slingerland, J.M. Obesity and adverse breast cancer risk and out-come: Mechanistic insights and strategies for intervention. CA Cancer J. Clin., 2017, 67(5), 378-397.
[http://dx.doi.org/10.3322/caac.21405] [PMID: 28763097]

Bodai, B.I.; Tuso, P. Breast cancer survivorship: a comprehensive review of long-term medical issues and lifestyle recommendations. Perm. J., 2015, 19(2), 48-79.
[http://dx.doi.org/10.7812/TPP/14-241] [PMID: 25902343]

Gray, J.M.; Rasanayagam, S.; Engel, C.; Rizzo, J. State of the Evidence 2017: An update on the connection between breast cancer and the environment. Environ. Health, 2017, 16(1), 94.
[http://dx.doi.org/10.1186/s12940-017-0287-4] [PMID: 28865460]

Shipitsin, M.; Campbell, L.L.; Argani, P.; Weremowicz, S.; Bloushtain-Qimron, N.; Yao, J.; Nikolskaya, T.; Serebryiskaya, T.; Beroukhim, R.; Hu, M.; Halushka, M.K.; Sukumar, S.; Parker, L.M.; Anderson, K.S.; Harris, L.N.; Garber, J.E.; Richardson, A.L.; Schnitt, S.J.; Ni-kolsky, Y.; Gelman, R.S.; Polyak, K. Molecular definition of breast tumor heterogeneity. Cancer Cell, 2007, 11(3), 259-273.
[http://dx.doi.org/10.1016/j.ccr.2007.01.013] [PMID: 17349583]

Hait, W.N. Anticancer drug development: the grand challenges. Nat. Rev. Drug Discov., 2010, 9(4), 253-254.
[http://dx.doi.org/10.1038/nrd3144] [PMID: 20369394]

Fonseca, N.C.; da Cruz, L.F.; da Silva Villela, F.; do Nascimento Pereira, G.A.; de Siqueira-Neto, J.L.; Kellar, D.; Suzuki, B.M.; Ray, D.; de Souza, T.B.; Alves, R.J.; Sales Júnior, P.A.; Romanha, A.J.; Murta, S.M.; McKerrow, J.H.; Caffrey, C.R.; de Oliveira, R.B.; Ferreira, R.S. Synthesis of a sugar-based thiosemicarbazone series and structure-activity relationship versus the parasite cysteine proteases rhodesain, cruzain, and Schistosoma mansoni cathepsin B1. Antimicrob. Agents Chemother., 2015, 59(5), 2666-2677.
[http://dx.doi.org/10.1128/AAC.04601-14] [PMID: 25712353]

Santos, B.M.D.; Gonzaga, D.T.G.; da Silva, F.C.; Ferreira, V.F.; Garcia, C.R.S. Plasmodium falciparum knockout for the GPCR-like PfSR25 receptor displays greater susceptibility to 1,2,3-triazole compounds that block malaria parasite development. Biomolecules, 2020, 10(8), 1197.
[http://dx.doi.org/10.3390/biom10081197] [PMID: 32824696]

Demoro, B.; Sarniguet, C.; Sánchez-Delgado, R.; Rossi, M.; Liebowitz, D.; Caruso, F.; Olea-Azar, C.; Moreno, V.; Medeiros, A.; Comini, M.A.; Otero, L.; Gambino, D. New organoruthenium complexes with bioactive thiosemicarbazones as co-ligands: Potential anti-trypanosomal agents. Dalton Trans., 2012, 41(5), 1534-1543.
[http://dx.doi.org/10.1039/C1DT11519G] [PMID: 22138896]

Papadopoulou, M.V.; Bloomer, W.D.; Rosenzweig, H.S.; Wilkinson, S.R.; Szular, J.; Kaiser, M. Antitrypanosomal activity of 5-nitro-2-aminothiazole-based compounds. Eur. J. Med. Chem., 2016, 117, 179-186.
[http://dx.doi.org/10.1016/j.ejmech.2016.04.010] [PMID: 27092415]

Haraguchi, S.K.; Silva, A.A.; Vidotti, G.J.; dos Santos, P.V.; Garcia, F.P.; Pedroso, R.B.; Nakamura, C.V.; de Oliveira, C.M.A.; da Silva, C.C. Antitrypanasomal activity of novel benzaldehyde-thiosemicarbazone derivatives from kaurenoic acid. Molecules, 2011, 16(2), 1166-1180.
[http://dx.doi.org/10.3390/molecules16021166] [PMID: 21270733]

Franklim, T.N.; Freire-de-Lima, L.; de Nazareth Sá Diniz, J.; Previato, J.O.; Castro, R.N.; Mendonça-Previato, L.; de Lima, M.E.F. Design, synthesis and trypanocidal evaluation of novel 1,2,4-triazoles-3-thiones derived from natural piperine. Molecules, 2013, 18(6), 6366-6382.
[http://dx.doi.org/10.3390/molecules18066366] [PMID: 23760033]

Borcea, A.M. Ionuț I.; Crișan, O.; Oniga, O. An Overview of the synthesis and antimicrobial, antiprotozoal, and antitumor activity of thiazole and bisthiazole derivatives. Molecules, 2021, 26(3), 624.
[http://dx.doi.org/10.3390/molecules26030624] [PMID: 33504100]

Álvarez, G.; Varela, J.; Cruces, E.; Fernández, M.; Gabay, M.; Leal, S.M.; Escobar, P.; Sanabria, L.; Serna, E.; Torres, S.; Figueredo Thiel, S.J.; Yaluff, G.; Vera de Bilbao, N.I.; Cerecetto, H.; González, M. Identification of a new amide-containing thiazole as a drug candidate for treatment of Chagas’ disease. Antimicrob. Agents Chemother., 2015, 59(3), 1398-1404.
[http://dx.doi.org/10.1128/AAC.03814-14] [PMID: 25512408]

Scarim, C.B.; Jornada, D.H.; Machado, M.G.M.; Ferreira, C.M.R.; Dos Santos, J.L.; Chung, M.C. Thiazole, thio and semicarbazone deriva-tives against tropical infective diseases: Chagas disease, human African trypanosomiasis (HAT), leishmaniasis, and malaria. Eur. J. Med. Chem., 2019, 162, 378-395.
[http://dx.doi.org/10.1016/j.ejmech.2018.11.013] [PMID: 30453246]

Rogolino, D.; Gatti, A.; Carcelli, M.; Pelosi, G.; Bisceglie, F.; Restivo, F.M.; Degola, F.; Buschini, A.; Montalbano, S.; Feretti, D.; Zani, C. Thiosemicarbazone scaffold for the design of antifungal and antiaflatoxigenic agents: Evaluation of ligands and related copper complexes. Sci. Rep., 2017, 7(1), 11214.
[http://dx.doi.org/10.1038/s41598-017-11716-w] [PMID: 28894265]

Cascioferro, S.; Parrino, B.; Carbone, D.; Schillaci, D.; Giovannetti, E.; Cirrincione, G.; Diana, P. Thiazoles, their benzofused systems, and thiazolidinone derivatives: Versatile and promising tools to combat antibiotic resistance. J. Med. Chem., 2020, 63(15), 7923-7956.
[http://dx.doi.org/10.1021/acs.jmedchem.9b01245] [PMID: 32208685]

Strzelecka, M. Pharmaceuticals (Basel), 2021, 14(3), 224.
[http://dx.doi.org/10.3390/ph14030224] [PMID: 33799936]

Mohammad, H.; Reddy, P.V.N.; Monteleone, D.; Mayhoub, A.S.; Cushman, M.; Hammac, G.K.; Seleem, M.N. Antibacterial Characteriza-tion of novel synthetic thiazole compounds against methicillin-resistant Staphylococcus pseudintermedius. PLoS One, 2015, 10(6)e0130385
[http://dx.doi.org/10.1371/journal.pone.0130385] [PMID: 26086336]

Khan, S.A.; Asiri, A.M.; Al-Amry, K.; Malik, M.A. Synthesis, characterization, electrochemical studies, and in vitro antibacterial activity of novel thiosemicarbazone and its Cu(II), Ni(II), and Co(II). Complexes. Sci. World J., 2014, 2014592375
[http://dx.doi.org/10.1155/2014/592375] [PMID: 24523641]

Ohui, K.; Afanasenko, E.; Bacher, F.; Ting, R.L.X.; Zafar, A.; Blanco-Cabra, N.; Torrents, E.; Dömötör, O.; May, N.V.; Darvasiova, D.; Enyedy, É.A. Popović-Bijelić A.; Reynisson, J.; Rapta, P.; Babak, M.V.; Pastorin, G.; Arion, V.B. New water-soluble copper(ii) complex-es with morpholine-thiosemicarbazone hybrids: Insights into the anticancer and antibacterial mode of action. J. Med. Chem., 2019, 62(2), 512-530.
[http://dx.doi.org/10.1021/acs.jmedchem.8b01031] [PMID: 30507173]

Oniga, S.D.; Araniciu, C.; Palage, M.D.; Popa, M.; Chifiriuc, M.C.; Marc, G.; Pirnau, A.; Stoica, C.I.; Lagoudis, I.; Dragoumis, T.; Oniga, O. New 2-phenylthiazoles as potential sortase A inhibitors: Synthesis, biological evaluation and molecular docking. Molecules, 2017, 22(11), 1827.
[http://dx.doi.org/10.3390/molecules22111827] [PMID: 29077016]

Li, Y.; Bionda, N.; Fleeman, R.; Wang, H.; Ozawa, A.; Houghten, R.A.; Shaw, L. Identification of 5,6-dihydroimidazo[2,1-b]thiazoles as a new class of antimicrobial agents. Bioorg. Med. Chem., 2016, 24(21), 5633-5638.
[http://dx.doi.org/10.1016/j.bmc.2016.09.027] [PMID: 27663549]

Zhang, J.; Van Den Heuvel, J.; Debets, A.J.M.; Verweij, P.E.; Melchers, W.J.G.; Zwaan, B.J.; Schoustra, S.E. Evolution of cross-resistance to medical triazoles in Aspergillus Fumigatus through selection pressure of environmental fungicides., 2017.

Vora, D.; Upadhyay, N.; Tilekar, K.; Jain, V.; Ramaa, C.S. Development of 1,2,4-triazole-5-thione derivatives as potential inhibitors of enoyl acyl carrier protein reductase (InhA) in tuberculosis. Iran. J. Pharm. Res., 2019, 18(4), 1742-1758.
[http://dx.doi.org/10.22037/ijpr.2019.112039.13495] [PMID: 32184843]

Venugopala, K.N.; Kandeel, M.; Pillay, M.; Deb, P.K.; Abdallah, H.H.; Mahomoodally, M.F.; Chopra, D. Anti-tubercular properties of 4-amino-5-(4-fluoro-3- phenoxyphenyl)-4H -1,2,4-triazole-3-thiol and its Schiff bases: Computational input and molecular dynamics. Antibiotics (Basel), 2020, 9(9), 559.
[http://dx.doi.org/10.3390/antibiotics9090559] [PMID: 32878018]

Karczmarzyk, Z.; Swatko-Ossor, M.; Wysocki, W.; Drozd, M.; Ginalska, G.; Pachuta-Stec, A.; Pitucha, M. New application of 1,2,4-triazole derivatives as antitubercular agents. Structure, in vitro screening and docking studies. Molecules, 2020, 25(24), 6033.
[http://dx.doi.org/10.3390/molecules25246033] [PMID: 33352814]

Yan, X.; Lv, Z.; Wen, J.; Zhao, S.; Xu, Z. Synthesis and in vitro evaluation of novel substituted isatin-propylene-1H-1,2,3-triazole-4-methylene-moxifloxacin hybrids for their anti-mycobacterial activities. Eur. J. Med. Chem., 2018, 143, 899-904.
[http://dx.doi.org/10.1016/j.ejmech.2017.11.090] [PMID: 29227930]

Garg, A.; Borah, D.; Trivedi, P.; Gogoi, D.; Chaliha, A.K.; Ali, A.A.; Chetia, D.; Chaturvedi, V.; Sarma, D. A Simple work-up-free, solvent-free approach to novel amino acid linked 1,4-disubstituted 1,2,3-triazoles as potent antituberculosis agents. ACS Omega, 2020, 5(46), 29830-29837.
[http://dx.doi.org/10.1021/acsomega.0c03862] [PMID: 33251417]

Özadali Sari, K.; Ünsal Tan, O.; Sriram, D.; Balkan, A. Some new hydrazone derivatives bearing the 1,2,4-triazole moiety as potential antimycobacterial agents. J. Pharm. Sci., 2019, 16(4), 432-436.
[http://dx.doi.org/10.4274/tjps.galenos.2018.43660] [PMID: 32454746]

Beteck, R.M.; Seldon, R.; Jordaan, A.; Warner, D.F.; Hoppe, H.C.; Laming, D.; Khanye, S.D. New quinolone-based thiosemicarbazones showing activity against Plasmodium falciparum and Mycobacterium tuberculosis. Molecules, 2019, 24(9), 1740.
[http://dx.doi.org/10.3390/molecules24091740] [PMID: 31060249]

Alsayed, S.S.R.; Lun, S.; Luna, G.; Beh, C.C.; Payne, A.D.; Foster, N.; Bishai, W.R.; Gunosewoyo, H. Design, synthesis, and biological evaluation of novel arylcarboxamide derivatives as anti-tubercular agents. RSC Advances, 2020, 10(13), 7523-7540.
[http://dx.doi.org/10.1039/C9RA10663D] [PMID: 33014349]

Moraski, G.C.; Deboosère, N.; Marshall, K.L.; Weaver, H.A.; Vandeputte, A.; Hastings, C.; Woolhiser, L.; Lenaerts, A.J.; Brodin, P.; Mil-ler, M.J. Intracellular and in vivo evaluation of imidazo[2,1-b]thiazole-5-carboxamide anti-tuberculosis compounds. PLoS One, 2020, 15(1)e0227224
[http://dx.doi.org/10.1371/journal.pone.0227224] [PMID: 31905374]

Geronikaki, A.; Hadjipavlou-Litina, D.; Zablotskaya, A.; Segal, I. Organosilicon-containing thiazole derivatives as potential lipoxygenase inhibitors and anti-inflammatory agents. Bioinorg. Chem. Appl., 2007, 2007, 92145.
[http://dx.doi.org/10.1155/2007/92145] [PMID: 18256725]

Shawish, H.B.; Wong, W.Y.; Wong, Y.L.; Loh, S.W.; Looi, C.Y.; Hassandarvish, P.; Phan, A.Y.L.; Wong, W.F.; Wang, H.; Paterson, I.C.; Ea, C.K.; Mustafa, M.R.; Maah, M.J. Nickel(II) complex of polyhydroxybenzaldehyde N4-thiosemicarbazone exhibits anti-inflammatory activity by inhibiting NF-κB transactivation. PLoS One, 2014, 9(6)e100933
[http://dx.doi.org/10.1371/journal.pone.0100933] [PMID: 24977407]

Oniga, S.D.; Pacureanu, L.; Stoica, C.I.; Palage, M.D. Crăciun, A.; Rusu, L.R.; Crisan, E.L.; Araniciu, C. COX Inhibition profile and mo-lecular docking studies of some 2-(trimethoxyphenyl)-thiazoles. Molecules, 2017, 22(9), 1507.
[http://dx.doi.org/10.3390/molecules22091507] [PMID: 28891941]

Al-Omar, M.A.; Al-Abdullah, E.S.; Shehata, I.A.; Habib, E.E.; Ibrahim, T.M.; El-Emam, A.A. Synthesis, antimicrobial, and anti-inflammatory activities of novel 5-(1-adamantyl)-4-arylideneamino-3-mercapto-1,2,4-triazoles and related derivatives. Molecules, 2010, 15(4), 2526-2550.
[http://dx.doi.org/10.3390/molecules15042526] [PMID: 20428062]

Kamat, V.; Santosh, R.; Poojary, B.; Nayak, S.P.; Kumar, B.K.; Sankaranarayanan, M. Faheem; Khanapure, S.; Barretto, D.A.; Vootla, S.K. Pyridine- and thiazole-based hydrazides with promising anti-inflammatory and antimicrobial activities along with their In Silico stud-ies. ACS Omega, 2020, 5(39), 25228-25239.
[http://dx.doi.org/10.1021/acsomega.0c03386] [PMID: 33043201]

Al-Abdullah, E.S.; Asiri, H.H.; Lahsasni, S.; Habib, E.E.; Ibrahim, T.M.; El-Emam, A.A. Synthesis, antimicrobial, and anti-inflammatory activity, of novel S-substituted and N-substituted 5-(1-adamantyl)-1,2,4-triazole-3-thiols. Drug Des. Devel. Ther., 2014, 8, 505-518.
[http://dx.doi.org/10.2147/DDDT.S62465] [PMID: 24872681]

Araniciu, C.; Pârvu, A.E.; Palage, M.D.; Oniga, S.D.; Benedec, D.; Oniga, I.; Oniga, O. The effect of some 4,2 and 5,2 bisthiazole deriva-tives on nitro-oxidative stress and phagocytosis in acute experimental inflammation. Molecules, 2014, 19(7), 9240-9256.
[http://dx.doi.org/10.3390/molecules19079240] [PMID: 24991757]

Liaras, K.; Fesatidou, M.; Geronikaki, A. Thiazoles and Thiazolidinones as COX/LOX Inhibitors. Molecules, 2018, 23(3), 685.
[http://dx.doi.org/10.3390/molecules23030685] [PMID: 29562646]

Assis, S.P.D.O.; da Silva, M.T.; de Oliveira, R.N.; Lima, V.L.D.M. Synthesis and anti-inflammatory activity of new alkyl-substituted phthalimide 1H-1,2,3-triazole derivatives. ScientificWorldJournal, 2012, 2012925925
[http://dx.doi.org/10.1100/2012/925925] [PMID: 23304092]

Galstyan, A.S.; Martiryan, A.I.; Grigoryan, K.R.; Ghazaryan, A.G.; Samvelyan, M.A.; Ghochikyan, T.V.; Nenajdenko, V.G. Synthesis of carvone-derived 1,2,3-triazoles study of their antioxidant properties and interaction with bovine serum albumin. Molecules, 2018, 23(11), 2991.
[http://dx.doi.org/10.3390/molecules23112991] [PMID: 30453471]

Yakan, H. Preparation, structure elucidation, and antioxidant activity of new bis(thiosemicarbazone) derivatives. Turk. J. Chem., 2020, 44(4), 1085-1099.
[http://dx.doi.org/10.3906/kim-2002-76] [PMID: 33488214]

Secci, D.; Carradori, S.; Petzer, A.; Guglielmi, P.; D’Ascenzio, M.; Chimenti, P.; Bagetta, D.; Alcaro, S.; Zengin, G.; Petzer, J.P.; Ortuso, F. 4-(3-nitrophenyl)thiazol-2-ylhydrazone derivatives as antioxidants and selective hMAO-B inhibitors: Synthesis, biological activity and computational analysis. J. Enzyme Inhib. Med. Chem., 2019, 34(1), 597-612.
[http://dx.doi.org/10.1080/14756366.2019.1571272] [PMID: 30727777]

Yehye, W.A.; Abdul Rahman, N.; Saad, O.; Ariffin, A.; Abd Hamid, S.B.; Alhadi, A.A.; Kadir, F.A.; Yaeghoobi, M.; Matlob, A.A. Rational design and synthesis of new, high efficiency, multipotent Schiff base-1,2,4-triazole antioxidants bearing butylated hydroxytoluene moie-ties. Molecules, 2016, 21(7), 847.
[http://dx.doi.org/10.3390/molecules21070847] [PMID: 27367658]

Nazarbahjat, N.; Nordin, N.; Abdullah, Z.; Abdulla, M.A.; Yehye, W.A.; Halim, S.N.A.; Kee, C.H.; Ariffin, A. New thiosemicarbazides and 1,2,4-triazolethiones derived from 2-(ethylsulfanyl) benzohydrazide as potent antioxidants. Molecules, 2014, 19(8), 11520-11537.
[http://dx.doi.org/10.3390/molecules190811520] [PMID: 25093989]

Nastasă C.; Tiperciuc, B.; Duma, M.; Benedec, D.; Oniga, O. New hydrazones bearing thiazole scaffold: Synthesis, characterization, anti-microbial, and antioxidant investigation. Molecules, 2015, 20(9), 17325-17338.
[http://dx.doi.org/10.3390/molecules200917325] [PMID: 26393564]

Barbuceanu, S.F.; Ilies, D.C.; Saramet, G.; Uivarosi, V.; Draghici, C.; Radulescu, V. Synthesis and antioxidant activity evaluation of new compounds from hydrazinecarbothioamide and 1,2,4-triazole class containing diarylsulfone and 2,4-difluorophenyl moieties. Int. J. Mol. Sci., 2014, 15(6), 10908-10925.
[http://dx.doi.org/10.3390/ijms150610908] [PMID: 24941252]

Yang, L.; Liu, H.; Xia, D.; Wang, S. Antioxidant properties of camphene-based thiosemicarbazones: experimental and theoretical evalua-tion. Molecules, 2020, 25(5), 1192.
[http://dx.doi.org/10.3390/molecules25051192] [PMID: 32155763]

Grozav, A.; Porumb, I.D. Găină L.I.; Filip, L.; Hanganu, D. Cytotoxicity and antioxidant potential of novel 2-(2-((1H-indol-5yl)methylene)-hydrazinyl)-thiazole Derivatives. Molecules, 2017, 22(2), 260.
[http://dx.doi.org/10.3390/molecules22020260] [PMID: 28208774]

Almasirad, A.; Mousavi, Z.; Tajik, M.; Assarzadeh, M.J.; Shafiee, A. Synthesis, analgesic and anti-inflammatory activities of new methyl-imidazolyl-1,3,4-oxadiazoles and 1,2,4-triazoles. Daru, 2014, 22(1), 22.
[http://dx.doi.org/10.1186/2008-2231-22-22] [PMID: 24450412]

Harris, H.M.; Eans, S.O.; Ganno, M.L.; Davis, J.C.; Dooley, C.T.; McLaughlin, J.P.; Nefzi, A. Antinociceptive activity of thiazole-containing cyclized DAMGO and Leu-(Met) enkephalin analogs. Org. Biomol. Chem., 2019, 17(21), 5305-5315.
[http://dx.doi.org/10.1039/C9OB00882A] [PMID: 31094391]

Pember, S.O.; Mejia, G.L.; Price, T.J.; Pasteris, R.J. Piperidinyl thiazole isoxazolines: A new series of highly potent, slowly reversible FAAH inhibitors with analgesic properties. Bioorg. Med. Chem. Lett., 2016, 26(12), 2965-2973.
[http://dx.doi.org/10.1016/j.bmcl.2016.02.061] [PMID: 27130358]

Saad, H.A.; Osman, N.A.; Moustafa, A.H. Synthesis and analgesic activity of some new pyrazoles and triazoles bearing a 6,8-dibromo-2-methylquinazoline moiety. Molecules, 2011, 16(12), 10187-10201.
[http://dx.doi.org/10.3390/molecules161210187] [PMID: 22157581]

Modi, G.; Antonio, T.; Reith, M.; Dutta, A. Structural modifications of neuroprotective anti-Parkinsonian (-)-N6-(2-(4-(biphenyl-4-yl)piperazin-1-yl)-ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine (D-264): an effort toward the improvement of in vivo efficacy of the parent molecule. J. Med. Chem., 2014, 57(4), 1557-1572.
[http://dx.doi.org/10.1021/jm401883v] [PMID: 24471976]

Kaproń B.; Łuszczki, J.; Paneth, A.; Wujec, M.; Siwek, A.; Karcz, T.; Mordyl, B.; Głuch-Lutwin, M.; Gryboś A.; Nowak, G.; Pająk, K.; Jóźwiak, K.; Tomczykowski, A.; Plech, T. Molecular mechanism of action and safety of 5-(3-chlorophenyl)-4-hexyl-2,4-dihydro-3H-1,2,4-triazole-3-thione - a novel anticonvulsant drug candidate. Int. J. Med. Sci., 2017, 14(8), 741-749.
[http://dx.doi.org/10.7150/ijms.20001] [PMID: 28824309]

Jiang, Z.G.; Lebowitz, M.S.; Ghanbari, H.A. Neuroprotective activity of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (PAN-811), a cancer therapeutic agent. CNS Drug Rev., 2006, 12(1), 77-90.
[http://dx.doi.org/10.1111/j.1527-3458.2006.00077.x] [PMID: 16834759]

Huuskonen, M.T.; Tuo, Q.Z.; Loppi, S.; Dhungana, H.; Korhonen, P.; McInnes, L.E.; Donnelly, P.S.; Grubman, A.; Wojciechowski, S.; Lejavova, K.; Pomeshchik, Y.; Periviita, L.; Kosonen, L.; Giordano, M.; Walker, F.R.; Liu, R.; Bush, A.I.; Koistinaho, J.; Malm, T.; White, A.R.; Lei, P.; Kanninen, K.M. The copper bis(thiosemicarbazone) complex CuII(atsm) is protective against cerebral ischemia through modulation of the inflammatory milieu. Neurotherapeutics, 2017, 14(2), 519-532.
[http://dx.doi.org/10.1007/s13311-016-0504-9] [PMID: 28050710]

Jones, M.R.; Mathieu, E.; Dyrager, C.; Faissner, S.; Vaillancourt, Z.; Korshavn, K.J.; Lim, M.H.; Ramamoorthy, A.; Wee Yong, V.; Tsut-sui, S.; Stys, P.K.; Storr, T. Multi-target-directed phenol-triazole ligands as therapeutic agents for Alzheimer’s disease. Chem. Sci. (Camb.), 2017, 8(8), 5636-5643.
[http://dx.doi.org/10.1039/C7SC01269A] [PMID: 28989601]

Bica, L.; Liddell, J.R.; Donnelly, P.S.; Duncan, C.; Caragounis, A.; Volitakis, I.; Paterson, B.M.; Cappai, R.; Grubman, A.; Camakaris, J.; Crouch, P.J.; White, A.R. Neuroprotective copper bis(thiosemicarbazonato) complexes promote neurite elongation. PLoS One, 2014, 9(2)e90070
[http://dx.doi.org/10.1371/journal.pone.0090070] [PMID: 24587210]

Qin, Z.; Luo, J.; VandeVrede, L.; Tavassoli, E.; Fa’, M.; Teich, A.F.; Arancio, O.; Thatcher, G.R.J. Design and synthesis of neuroprotec-tive methylthiazoles and modification as NO-chimeras for neurodegenerative therapy. J. Med. Chem., 2012, 55(15), 6784-6801.
[http://dx.doi.org/10.1021/jm300353r] [PMID: 22779770]

Avila, B.; Roth, A.; Streets, H.; Dwyer, D.S.; Kurth, M.J. Triazolbenzo[d]thiazoles: Efficient synthesis and biological evaluation as neuro-protective agents. Bioorg. Med. Chem. Lett., 2012, 22(18), 5976-5978.
[http://dx.doi.org/10.1016/j.bmcl.2012.07.022] [PMID: 22892117]

Ghosh, B.; Antonio, T.; Zhen, J.; Kharkar, P.; Reith, M.E.A.; Dutta, A.K. Development of (S)-N6-(2-(4-(isoquinolin-1-yl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]-thiazole-2,6-diamine and its analogue as a D3 receptor preferring agonist: potent in vivo activity in Parkinson’s disease animal models. J. Med. Chem., 2010, 53(3), 1023-1037.
[http://dx.doi.org/10.1021/jm901184n] [PMID: 20038106]

Ferroni, C.; Pepe, A.; Kim, Y.S.; Lee, S.; Guerrini, A.; Parenti, M.D.; Tesei, A.; Zamagni, A.; Cortesi, M.; Zaffaroni, N.; De Cesare, M.; Beretta, G.L.; Trepel, J.B.; Malhotra, S.V.; Varchi, G. 1,4-substituted triazoles as nonsteroidal anti-androgens for prostate cancer treatment. J. Med. Chem., 2017, 60(7), 3082-3093.
[http://dx.doi.org/10.1021/acs.jmedchem.7b00105] [PMID: 28272894]

Serda, M.; Kalinowski, D.S.; Rasko, N. Potůčková, E.; Mrozek-Wilczkiewicz, A.; Musiol, R.; Małecki, J.G.; Sajewicz, M.; Ratuszna, A.; Muchowicz, A.; Gołąb, J.; Simůnek, T.; Richardson, D.R.; Polanski, J. Exploring the anti-cancer activity of novel thiosemicarbazones gen-erated through the combination of retro-fragments: dissection of critical structure-activity relationships. PLoS One, 2014, 9(10)e110291
[http://dx.doi.org/10.1371/journal.pone.0110291] [PMID: 25329549]

Karlsson, H.; Fryknäs, M.; Strese, S.; Gullbo, J.; Westman, G.; Bremberg, U.; Sjöblom, T.; Pandzic, T.; Larsson, R.; Nygren, P. Mechanis-tic characterization of a copper containing thiosemicarbazone with potent antitumor activity. Oncotarget, 2017, 8(18), 30217-30234.
[http://dx.doi.org/10.18632/oncotarget.16324] [PMID: 28415818]

Yalowich, J.C.; Wu, X.; Zhang, R.; Kanagasabai, R.; Hornbaker, M.; Hasinoff, B.B. The anticancer thiosemicarbazones Dp44mT and triap-ine lack inhibitory effects as catalytic inhibitors or poisons of DNA topoisomerase II&#945. Biochem. Pharmacol., 2012, 84(1), 52-58.
[http://dx.doi.org/10.1016/j.bcp.2012.03.021] [PMID: 22503743]

Althagafi, I.; El-Metwaly, N.; Farghaly, T.A. New series of thiazole derivatives: Synthesis, structural elucidation, antimicrobial activity, molecular modeling and MOE docking. Molecules, 2019, 24(9), 1741.
[http://dx.doi.org/10.3390/molecules24091741] [PMID: 31060260]

Costa, A.V.; Oliveira, M.V.L.; Pinto, R.T.; Moreira, L.C.; Gomes, E.M.C.; Alves, T.A.; Pinheiro, P.F.; Queiroz, V.T.; Vieira, L.F.A.; Teixeira, R.R.; Júnior, W.C.J. Synthesis of novel glycerol-derived 1,2,3-triazoles and evaluation of their fungicide, phytotoxic and cytotox-ic activities. Molecules, 2017, 22(10), 1666.
[http://dx.doi.org/10.3390/molecules22101666] [PMID: 28991165]

Altıntop, M.D.; Temel, H.E.; Sever, B.; Akalın Çiftçi, G.; Kaplancıklı Z.A. Synthesis and evaluation of new benzodioxole- based thio-semicarbazone derivatives as potential antitumor agents. Molecules, 2016, 21(11), 1598.
[http://dx.doi.org/10.3390/molecules21111598] [PMID: 27879683]

Bormio Nunes, J.H.; Hager, S.; Mathuber, M.; Pósa, V.; Roller, A.; Enyedy, É.A.; Stefanelli, A.; Berger, W.; Keppler, B.K.; Heffeter, P.; Kowol, C.R. Cancer cell resistance against the clinically investigated thiosemicarbazone COTI-2 is based on formation of intracellular cop-per complex glutathione adducts and ABCC1-mediated efflux. J. Med. Chem., 2020, 63(22), 13719-13732.
[http://dx.doi.org/10.1021/acs.jmedchem.0c01277] [PMID: 33190481]

Mabkhot, Y.N.; Alharbi, M.M.; Al-Showiman, S.S.; Ghabbour, H.A.; Kheder, N.A.; Soliman, S.M.; Frey, W. Stereoselective synthesis, X-ray analysis, computational studies and biological evaluation of new thiazole derivatives as potential anticancer agents. Chem. Cent. J., 2018, 12(1), 56.
[http://dx.doi.org/10.1186/s13065-018-0420-7] [PMID: 29748782]

Papadopoulou, M.V.; Ji, M.; Bloomer, W.D. Novel fluorinated hypoxia-targeted compounds as Non-invasive probes for measuring tumor-hypoxia by 19F-magnetic resonance spectroscopy (19F-MRS). Anticancer Res., 2006, 26(5A), 3253-3258.
[PMID: 17094437]

Papadopoulou, M.V.; Bloomer, W.D.; Rosenzweig, H.S.; Chatelain, E.; Kaiser, M.; Wilkinson, S.R.; McKenzie, C.; Ioset, J.R. Novel 3-nitro-1H-1,2,4-triazole-based amides and sulfonamides as potential antitrypanosomal agents. J. Med. Chem., 2012, 55(11), 5554-5565.
[http://dx.doi.org/10.1021/jm300508n] [PMID: 22550999]

Zhao, M.Y.; Yin, Y.; Yu, X.W.; Sangani, C.B.; Wang, S.F.; Lu, A.M.; Yang, L.F.; Lv, P.C.; Jiang, M.G.; Zhu, H.L. Synthesis, biological evaluation and 3D-QSAR study of novel 4,5-dihydro-1H-pyrazole thiazole derivatives as BRAF(V⁶⁰⁰E) inhibitors. Bioorg. Med. Chem., 2015, 23(1), 46-54.
[http://dx.doi.org/10.1016/j.bmc.2014.11.029] [PMID: 25496804]

Today, C. 2021.https://gco.iarc.fr/today/fact-sheets-cancers

2021.https://www.who.int/cancer/detection/breastcancer/en/

Ho, W.K.; Tan, M.M.; Mavaddat, N.; Tai, M.C.; Mariapun, S.; Li, J.; Ho, P.J.; Dennis, J.; Tyrer, J.P.; Bolla, M.K.; Michailidou, K.; Wang, Q.; Kang, D.; Choi, J.Y.; Jamaris, S.; Shu, X.O.; Yoon, S.Y.; Park, S.K.; Kim, S.W.; Shen, C.Y.; Yu, J.C.; Tan, E.Y.; Chan, P.M.Y.; Muir, K.; Lophatananon, A.; Wu, A.H.; Stram, D.O.; Matsuo, K.; Ito, H.; Chan, C.W.; Ngeow, J.; Yong, W.S.; Lim, S.H.; Lim, G.H.; Kwong, A.; Chan, T.L.; Tan, S.M.; Seah, J.; John, E.M.; Kurian, A.W.; Koh, W.P.; Khor, C.C.; Iwasaki, M.; Yamaji, T.; Tan, K.M.V.; Tan, K.T.B.; Spinelli, J.J.; Aronson, K.J.; Hasan, S.N.; Rahmat, K.; Vijayananthan, A.; Sim, X.; Pharoah, P.D.P.; Zheng, W.; Dunning, A.M.; Simard, J.; van Dam, R.M.; Yip, C.H.; Taib, N.A.M.; Hartman, M.; Easton, D.F.; Teo, S.H.; Antoniou, A.C. European polygenic risk score for predic-tion of breast cancer shows similar performance in Asian women. Nat. Commun., 2020, 11(1), 3833.
[http://dx.doi.org/10.1038/s41467-020-17680-w] [PMID: 32737321]

Howell, A.; Anderson, A.S.; Clarke, R.B.; Duffy, S.W.; Evans, D.G.; Garcia-Closas, M.; Gescher, A.J.; Key, T.J.; Saxton, J.M.; Harvie, M.N. Risk determination and prevention of breast cancer. Breast Cancer Res., 2014, 16(5), 446.
[http://dx.doi.org/10.1186/s13058-014-0446-2] [PMID: 25467785]

Mavaddat, N.; Pharoah, P.D.P.; Michailidou, K.; Tyrer, J.; Brook, M.N.; Bolla, M.K.; Wang, Q.; Dennis, J.; Dunning, A.M.; Shah, M.; Lu-ben, R.; Brown, J.; Bojesen, S.E.; Nordestgaard, B.G.; Nielsen, S.F.; Flyger, H.; Czene, K.; Darabi, H.; Eriksson, M.; Peto, J.; Dos-Santos-Silva, I.; Dudbridge, F.; Johnson, N.; Schmidt, M.K.; Broeks, A.; Verhoef, S.; Rutgers, E.J.; Swerdlow, A.; Ashworth, A.; Orr, N.; Schoe-maker, M.J.; Figueroa, J.; Chanock, S.J.; Brinton, L.; Lissowska, J.; Couch, F.J.; Olson, J.E.; Vachon, C.; Pankratz, V.S.; Lambrechts, D.; Wildiers, H.; Van Ongeval, C.; van Limbergen, E.; Kristensen, V.; Grenaker Alnæs, G.; Nord, S.; Borresen-Dale, A.L.; Nevanlinna, H.; Muranen, T.A.; Aittomäki, K.; Blomqvist, C.; Chang-Claude, J.; Rudolph, A.; Seibold, P.; Flesch-Janys, D.; Fasching, P.A.; Haeberle, L.; Ekici, A.B.; Beckmann, M.W.; Burwinkel, B.; Marme, F.; Schneeweiss, A.; Sohn, C.; Trentham-Dietz, A.; Newcomb, P.; Titus, L.; Egan, K.M.; Hunter, D.J.; Lindstrom, S.; Tamimi, R.M.; Kraft, P.; Rahman, N.; Turnbull, C.; Renwick, A.; Seal, S.; Li, J.; Liu, J.; Humphreys, K.; Benitez, J.; Pilar Zamora, M.; Arias Perez, J.I.; Menéndez, P.; Jakubowska, A.; Lubinski, J.; Jaworska-Bieniek, K.; Durda, K.; Bogdanova, N.V.; Antonenkova, N.N.; Dörk, T.; Anton-Culver, H.; Neuhausen, S.L.; Ziogas, A.; Bernstein, L.; Devilee, P.; Tollenaar, R.A.; Seynaeve, C.; van Asperen, C.J.; Cox, A.; Cross, S.S.; Reed, M.W.; Khusnutdinova, E.; Bermisheva, M.; Prokofyeva, D.; Takhirova, Z.; Meindl, A.; Schmutzler, R.K.; Sutter, C.; Yang, R.; Schürmann, P.; Bremer, M.; Christiansen, H.; Park-Simon, T.W.; Hillemanns, P.; Guénel, P.; Tru-ong, T.; Menegaux, F.; Sanchez, M.; Radice, P.; Peterlongo, P.; Manoukian, S.; Pensotti, V.; Hopper, J.L.; Tsimiklis, H.; Apicella, C.; Sou-they, M.C.; Brauch, H.; Brüning, T.; Ko, Y.D.; Sigurdson, A.J.; Doody, M.M.; Hamann, U.; Torres, D.; Ulmer, H.U.; Försti, A.; Sawyer, E.J.; Tomlinson, I.; Kerin, M.J.; Miller, N.; Andrulis, I.L.; Knight, J.A.; Glendon, G.; Marie Mulligan, A.; Chenevix-Trench, G.; Balleine, R.; Giles, G.G.; Milne, R.L.; McLean, C.; Lindblom, A.; Margolin, S.; Haiman, C.A.; Henderson, B.E.; Schumacher, F.; Le Marchand, L.; Eilber, U.; Wang-Gohrke, S.; Hooning, M.J.; Hollestelle, A.; van den Ouweland, A.M.; Koppert, L.B.; Carpenter, J.; Clarke, C.; Scott, R.; Mannermaa, A.; Kataja, V.; Kosma, V.M.; Hartikainen, J.M.; Brenner, H.; Arndt, V.; Stegmaier, C.; Karina Dieffenbach, A.; Winqvist, R.; Pylkäs, K.; Jukkola-Vuorinen, A.; Grip, M.; Offit, K.; Vijai, J.; Robson, M.; Rau-Murthy, R.; Dwek, M.; Swann, R.; Annie Perkins, K.; Goldberg, M.S.; Labrèche, F.; Dumont, M.; Eccles, D.M.; Tapper, W.J.; Rafiq, S.; John, E.M.; Whittemore, A.S.; Slager, S.; Yannoukakos, D.; Toland, A.E.; Yao, S.; Zheng, W.; Halverson, S.L.; González-Neira, A.; Pita, G.; Rosario Alonso, M.; Álvarez, N.; Herrero, D.; Tessier, D.C.; Vincent, D.; Bacot, F.; Luccarini, C.; Baynes, C.; Ahmed, S.; Maranian, M.; Healey, C.S.; Simard, J.; Hall, P.; Easton, D.F.; Garcia-Closas, M. Prediction of breast cancer risk based on profiling with common genetic variants. J. Natl. Cancer Inst., 2015, 107(5)djv036
[http://dx.doi.org/10.1093/jnci/djv036] [PMID: 25855707]

Koriech, O.M. Breast cancer and early detection. J. Family Community Med., 1996, 3(1), 7-9.
[PMID: 23008541]

Carbine, N.E.; Lostumbo, L.; Wallace, J.; Ko, H. Risk-reducing mastectomy for the prevention of primary breast cancer. Cochrane Database Syst. Rev., 2018, 4(4)CD002748
[http://dx.doi.org/10.1002/14651858.CD002748.pub4] [PMID: 29620792]

Rebbeck, T.R.; Burns-White, K.; Chan, A.T.; Emmons, K.; Freedman, M.; Hunter, D.J.; Kraft, P.; Laden, F.; Mucci, L.; Parmigiani, G.; Schrag, D.; Syngal, S.; Tamimi, R.M.; Viswanath, K.; Yurgelun, M.B.; Garber, J.E. Precision prevention and early detection of cancer: Fundamental principles. Cancer Discov., 2018, 8(7), 803-811.
[http://dx.doi.org/10.1158/2159-8290.CD-17-1415] [PMID: 29907587]

Greenlee, H.; DuPont-Reyes, M.J.; Balneaves, L.G.; Carlson, L.E.; Cohen, M.R.; Deng, G.; Johnson, J.A.; Mumber, M.; Seely, D.; Zick, S.M.; Boyce, L.M.; Tripathy, D. Clinical practice guidelines on the evidence-based use of integrative therapies during and after breast can-cer treatment. CA Cancer J. Clin., 2017, 67(3), 194-232.
[http://dx.doi.org/10.3322/caac.21397] [PMID: 28436999]

Rosenberg, B.; VanCamp, L.; Trosko, J.E.; Mansour, V.H. Platinum compounds: A new class of potent antitumour agents. Nature, 1969, 222(5191), 385-386.
[http://dx.doi.org/10.1038/222385a0] [PMID: 5782119]

Li, X.Q.; Ren, J.; Chen, P.; Chen, Y.J.; Wu, M.; Wu, Y.; Chen, K.; Li, J. Co-inhibition of Pol η and ATR sensitizes cisplatin-resistant non-small cell lung cancer cells to cisplatin by impeding DNA damage repair. Acta Pharmacol. Sin., 2018, 39(8), 1359-1372.
[http://dx.doi.org/10.1038/aps.2017.187] [PMID: 29849128]

Yimit, A.; Adebali, O.; Sancar, A.; Jiang, Y. Differential damage and repair of DNA-adducts induced by anti-cancer drug cisplatin across mouse organs. Nat. Commun., 2019, 10(1), 309.
[http://dx.doi.org/10.1038/s41467-019-08290-2] [PMID: 30659176]

Melnikov, S.V.; Söll, D.; Steitz, T.A.; Polikanov, Y.S. Insights into RNA binding by the anticancer drug cisplatin from the crystal structure of cisplatin-modified ribosome. Nucleic Acids Res., 2016, 44(10), 4978-4987.
[http://dx.doi.org/10.1093/nar/gkw246] [PMID: 27079977]

Dugbartey, G.J.; Peppone, L.J.; de Graaf, I.A.M. An integrative view of cisplatin-induced renal and cardiac toxicities: Molecular mecha-nisms, current treatment challenges and potential protective measures. Toxicology, 2016, 371(585), 58-66.
[http://dx.doi.org/10.1016/j.tox.2016.10.001] [PMID: 27717837]

Matthews, S.B.; Sartorius, C.A. Steroid hormone receptor positive breast cancer patient-derived xenografts. Horm. Cancer, 2017, 8(1), 4-15.
[http://dx.doi.org/10.1007/s12672-016-0275-0] [PMID: 27796944]

Burns, K.A.; Korach, K.S. Estrogen receptors and human disease: An update. Arch. Toxicol., 2012, 86(10), 1491-1504.
[http://dx.doi.org/10.1007/s00204-012-0868-5] [PMID: 22648069]

Sasanuma, H.; Tsuda, M.; Morimoto, S.; Saha, L.K.; Rahman, M.M.; Kiyooka, Y.; Fujiike, H.; Cherniack, A.D.; Itou, J.; Callen Moreu, E.; Toi, M.; Nakada, S.; Tanaka, H.; Tsutsui, K.; Yamada, S.; Nussenzweig, A.; Takeda, S. BRCA1 ensures genome integrity by eliminating estrogen-induced pathological topoisomerase II-DNA complexes. Proc. Natl. Acad. Sci. USA, 2018, 115(45), E10642-E10651.
[http://dx.doi.org/10.1073/pnas.1803177115] [PMID: 30352856]

Moore, R.L.; Faller, D.V. SIRT1 represses estrogen-signaling, ligand-independent ERα-mediated transcription, and cell proliferation in estrogen-responsive breast cells. J. Endocrinol., 2013, 216(3), 273-285.
[http://dx.doi.org/10.1530/JOE-12-0102] [PMID: 23169992]

Choi, H.J.; Lui, A.; Ogony, J.; Jan, R.; Sims, P.J.; Lewis-Wambi, J. Targeting interferon response genes sensitizes aromatase inhibitor re-sistant breast cancer cells to estrogen-induced cell death. Breast Cancer Res., 2015, 17(1), 6.
[http://dx.doi.org/10.1186/s13058-014-0506-7] [PMID: 25588716]

Fan, P.; Maximov, P.Y.; Curpan, R.F.; Abderrahman, B.; Jordan, V.C. The molecular, cellular and clinical consequences of targeting the estrogen receptor following estrogen deprivation therapy. Mol. Cell. Endocrinol., 2015, 418(Pt 3), 245-263.
[http://dx.doi.org/10.1016/j.mce.2015.06.004] [PMID: 26052034]

Abbondanza, C.; Rossi, V.; Roscigno, A.; Gallo, L.; Belsito, A.; Piluso, G.; Medici, N.; Nigro, V.; Molinari, A.M.; Moncharmont, B.; Puca, G.A. Interaction of vault particles with estrogen receptor in the MCF-7 breast cancer cell. J. Cell Biol., 1998, 141(6), 1301-1310.
[http://dx.doi.org/10.1083/jcb.141.6.1301] [PMID: 9628887]

Dalenc, F.; Giamarchi, C.; Petit, M.; Poirot, M.; Favre, G.; Faye, J.C. Farnesyl-transferase inhibitor R115,777 enhances tamoxifen inhibi-tion of MCF-7 cell growth through estrogen receptor dependent and independent pathways. Breast Cancer Res., 2005, 7(6), R1159-R1167.
[http://dx.doi.org/10.1186/bcr1357] [PMID: 16457696]

Iqbal, J.; Ejaz, S.A.; Khan, I.; Ausekle, E.; Miliutina, M.; Langer, P. Exploration of quinolone and quinoline derivatives as potential anti-cancer agents. Daru, 2019, 27(2), 613-626.
[http://dx.doi.org/10.1007/s40199-019-00290-3] [PMID: 31410781]

Sorokin, D.; Shchegolev, Y.; Scherbakov, A.; Ryabaya, O.; Gudkova, M.; Berstein, L.; Krasil’nikov, M. 2020.

Taslim, C.; Lin, S.; Huang, K.; Huang, T.H.M. Integrative genome-wide chromatin signature analysis using finite mixture models. BMC Genomics, 2012, 13(Suppl. 6), S3.
[http://dx.doi.org/10.1186/1471-2164-13-S6-S3] [PMID: 23134707]

Badran, A.; Tul-Wahab, A.; Zafar, H.; Mohammad, N.; Imad, R.; Ashfaq Khan, M.; Baydoun, E.; Choudhary, M.I. Antipsychotics drug aripiprazole as a lead against breast cancer cell line (MCF-7) in vitro. PLoS One, 2020, 15(8)e0235676
[http://dx.doi.org/10.1371/journal.pone.0235676] [PMID: 32746451]

Zhang, N.; Wang, J.; Sheng, A.; Huang, S.; Tang, Y.; Ma, S.; Hong, G. Emodin inhibits the proliferation of MCF-7 human breast cancer cells through activation of Aryl hydrocarbon receptor (AhR). Front. Pharmacol., 2021, 11622046
[http://dx.doi.org/10.3389/fphar.2020.622046] [PMID: 33542691]

Paramanantham, A.; Kim, M.J.; Jung, E.J.; Kim, H.J.; Chang, S.H.; Jung, J.M.; Hong, S.C.; Shin, S.C.; Kim, G.S.; Lee, W.S. Anthocyanins isolated from Vitis coignetiae Pulliat enhances cisplatin sensitivity in MCF-7 human breast cancer cells through inhibition of Akt and NF-κB activation. Molecules, 2020, 25(16), 3623.
[http://dx.doi.org/10.3390/molecules25163623] [PMID: 32784919]

Gomes, L.R.; Rocha, C.R.R.; Martins, D.J.; Fiore, A.P.Z.P.; Kinker, G.S.; Bruni-Cardoso, A.; Menck, C.F.M. ATR mediates cisplatin re-sistance in 3D-cultured breast cancer cells via translesion DNA synthesis modulation. Cell Death Dis., 2019, 10(6), 459.
[http://dx.doi.org/10.1038/s41419-019-1689-8] [PMID: 31189884]

Mi, H.; Wang, X.; Wang, F.; Li, L.; Zhu, M.; Wang, N.; Xiong, Y.; Gu, Y. SNHG15 contributes to cisplatin resistance in breast cancer through sponging miR-381. OncoTargets Ther., 2020, 13, 657-666.
[http://dx.doi.org/10.2147/OTT.S223321] [PMID: 32021307]

Kashkoulinejad-Kouhi, T.; Safarian, S.; Arnaiz, B.; Saa, L. Enhancement of cisplatin sensitivity in human breast cancer MCF-7 cell line through BiP and 14-3-3ζ co-knockdown. Oncol. Rep., 2021, 45(2), 665-679.
[http://dx.doi.org/10.3892/or.2020.7898] [PMID: 33416155]

Liao, S.; Hu, X.; Liu, Z.; Lin, Y.; Liang, R.; Zhang, Y.; Li, Q.; Li, Y.; Liao, X. Synergistic action of microwave-induced mild hyperthermia and paclitaxel in inducing apoptosis in the human breast cancer cell line MCF-7. Oncol. Lett., 2019, 17(1), 603-615.
[http://dx.doi.org/10.3892/ol.2018.9629] [PMID: 30655807]

Zhu, X.; Feng, J.; Fu, W.; Shu, X.; Wan, X.; Liu, J. Effects of cisplatin on the proliferation, invasion and apoptosis of breast cancer cells following β catenin silencing. Int. J. Mol. Med., 2020, 45(6), 1838-1850.
[http://dx.doi.org/10.3892/ijmm.2020.4543] [PMID: 32186756]

Reile, H.; Bernhardt, G.; Koch, M.; Schönenberger, H.; Hollstein, M.; Lux, F. Chemosensitivity of human MCF-7 breast cancer cells to diastereoisomeric diaqua(1,2-diphenylethylenediamine) platinum(II) sulfates and specific platinum accumulation. Cancer Chemother. Pharmacol., 1992, 30(2), 113-122.
[http://dx.doi.org/10.1007/BF00686402] [PMID: 1600591]

Kandeil, M.A.; Gomaa, S.B.; Mahmoud, M.O. The effect of some natural antioxidants against cisplatin-induced neurotoxicity in rats: be-havioral testing. Heliyon, 2020, 6(8)e04708
[http://dx.doi.org/10.1016/j.heliyon.2020.e04708] [PMID: 32885073]

Landau, S.I.; Guo, X.; Velazquez, H.; Torres, R.; Olson, E.; Garcia-Milian, R.; Moeckel, G.W.; Desir, G.V.; Safirstein, R. Regulated necro-sis and failed repair in cisplatin-induced chronic kidney disease. Kidney Int., 2019, 95(4), 797-814.
[http://dx.doi.org/10.1016/j.kint.2018.11.042] [PMID: 30904067]

Ozkok, A.; Edelstein, C.L. Pathophysiology of cisplatin-induced acute kidney injury. BioMed Res. Int., 2014, 2014967826
[http://dx.doi.org/10.1155/2014/967826] [PMID: 25165721]

Zhou, J.; Fan, Y.; Zhong, J.; Huang, Z.; Huang, T.; Lin, S.; Chen, H. TAK1 mediates excessive autophagy via p38 and ERK in cisplatin-induced acute kidney injury. J. Cell. Mol. Med., 2018, 22(5), 2908-2921.
[http://dx.doi.org/10.1111/jcmm.13585] [PMID: 29504713]

Mapuskar, K.A.; Wen, H.; Holanda, D.G.; Rastogi, P.; Steinbach, E.; Han, R.; Coleman, M.C.; Attanasio, M.; Riley, D.P.; Spitz, D.R.; Allen, B.G.; Zepeda-Orozco, D. Persistent increase in mitochondrial superoxide mediates cisplatin-induced chronic kidney disease. Redox Biol., 2019, 20, 98-106.
[http://dx.doi.org/10.1016/j.redox.2018.09.020] [PMID: 30296702]

Perše, M. Večerić-Haler, Ž. Cisplatin-induced rodent model of kidney injury: Characteristics and challenges. BioMed Res. Int., 2018, 20181462802
[http://dx.doi.org/10.1155/2018/1462802] [PMID: 30276200]

Holditch, S.J.; Brown, C.N.; Lombardi, A.M.; Nguyen, K.N.; Edelstein, C.L. Recent advances in models, mechanisms, biomarkers, and interventions in cisplatin-induced acute kidney injury. Int. J. Mol. Sci., 2019, 20(12), 3011.
[http://dx.doi.org/10.3390/ijms20123011] [PMID: 31226747]

Dupre, T.V.; Doll, M.A.; Shah, P.P.; Sharp, C.N.; Siow, D.; Megyesi, J.; Shayman, J.; Bielawska, A.; Bielawski, J.; Beverly, L.J. Hernan-dez-Corbacho, M.; Clarke, C.J.; Snider, A.J.; Schnellmann, R.G.; Obeid, L.M.; Hannun, Y.A.; Siskind, L.J. Inhibiting glucosylceramide synthase exacerbates cisplatin-induced acute kidney injury. J. Lipid Res., 2017, 58(7), 1439-1452.
[http://dx.doi.org/10.1194/jlr.M076745] [PMID: 28490444]

Tanase, D.M.; Gosav, E.M.; Radu, S.; Costea, C.F.; Ciocoiu, M.; Carauleanu, A.; Lacatusu, C.M.; Maranduca, M.A.; Floria, M.; Rezus, C. The predictive role of the biomarker kidney molecule-1 (KIM-1) in acute kidney injury (AKI) cisplatin-induced nephrotoxicity. Int. J. Mol. Sci., 2019, 20(20), 5238.
[http://dx.doi.org/10.3390/ijms20205238] [PMID: 31652595]

Xu, Q.; Liu, C.; Zang, J.; Gao, S.; Chou, C.J.; Zhang, Y. Discovery of a novel hybrid of vorinostat and riluzole as a potent antitumor agent. Front. Cell Dev. Biol., 2020, 8, 454.
[http://dx.doi.org/10.3389/fcell.2020.00454] [PMID: 32760715]

Trotsko, N.; Przekora, A.; Zalewska, J.; Ginalska, G.; Paneth, A.; Wujec, M. Synthesis and in vitro antiproliferative and antibacterial activi-ty of new thiazolidine-2,4-dione derivatives. J. Enzyme Inhib. Med. Chem., 2018, 33(1), 17-24.
[http://dx.doi.org/10.1080/14756366.2017.1387543] [PMID: 29098896]

Hosny, M.A.; Zaki, Y.H.; Mokbel, W.A.; Abdelhamid, A.O. Synthesis of novel thiazole, pyranothiazole, thiazolo[4,5-b]pyridines and thiazolo[5,4:5,6] pyrano[2,3-d]pyrimidine derivatives and incorporating isoindoline-1,3-dione group. BMC Chem., 2019, 13(1), 37.
[http://dx.doi.org/10.1186/s13065-019-0559-x] [PMID: 31384785]

2018.

Vaddula, B.R.; Tantak, M.P.; Sadana, R.; Gonzalez, M.A.; Kumar, D. One-pot synthesis and in-vitro anticancer evaluation of 5-(2′-indolyl)thiazoles. Sci. Rep., 2016, 6, 23401.
[http://dx.doi.org/10.1038/srep23401] [PMID: 27021742]

Abu-Melha, S.; Edrees, M.M.; Salem, H.H.; Kheder, N.A.; Gomha, S.M.; Abdelaziz, M.R. Synthesis and biological evaluation of some novel thiazole-based heterocycles as potential anticancer and antimicrobial agents. Molecules, 2019, 24(3), 539.
[http://dx.doi.org/10.3390/molecules24030539] [PMID: 30717217]

Al-Omair, M.A.; Sayed, A.R.; Youssef, M.M. Synthesis and biological evaluation of bisthiazoles and polythiazoles. Molecules, 2018, 23(5), 1133.
[http://dx.doi.org/10.3390/molecules23051133] [PMID: 29747479]

Atamanyuk, D.; Zimenkovsky, B.; Atamanyuk, V.; Nektegayev, I.; Lesyk, R. Synthesis and biological activity of new thiopyrano[2,3-d]thiazoles containing a naphthoquinone moiety. Sci. Pharm., 2013, 81(2), 423-436.
[http://dx.doi.org/10.3797/scipharm.1301-13] [PMID: 23833711]

Zaki, Y.H.; Al-Gendey, M.S.; Abdelhamid, A.O. A facile synthesis, and antimicrobial and anticancer activities of some pyridines, thioam-ides, thiazole, urea, quinazoline, β-naphthyl carbamate, and pyrano[2,3-d]thiazole derivatives. Chem. Cent. J., 2018, 12(1), 70.
[http://dx.doi.org/10.1186/s13065-018-0439-9] [PMID: 29926299]

Xun-Zhong, Z.; An-Sheng, F.; Fu-Ran, Z.; Min-Cheng, L.; Yan-Zhi, L.; Meng, M.; Yu, L. Synthesis, crystal structures, and antimicrobial and antitumor studies of two zinc(II) complexes with pyridine thiazole derivatives. Bioinorg. Chem. Appl., 2020, 20208852470
[http://dx.doi.org/10.1155/2020/8852470] [PMID: 33014027]

Liu, D.C.; Gao, M.J.; Huo, Q.; Ma, T.; Wang, Y.; Wu, C.Z. Design, synthesis, and apoptosis-promoting effect evaluation of novel pyrazole with benzo[d]thiazole derivatives containing aminoguanidine units. J. Enzyme Inhib. Med. Chem., 2019, 34(1), 829-837.
[http://dx.doi.org/10.1080/14756366.2019.1591391] [PMID: 30915869]

Spanò, V.; Attanzio, A.; Cascioferro, S.; Carbone, A.; Montalbano, A.; Barraja, P.; Tesoriere, L.; Cirrincione, G.; Diana, P.; Parrino, B. Synthesis and antitumor activity of new thiazole nortopsentin analogs. Mar. Drugs, 2016, 14(12), 226.
[http://dx.doi.org/10.3390/md14120226] [PMID: 27983614]

Turan-Zitouni, G. Yurttaş L.; Tabbi, A.; Akalın Çiftçi, G.; Temel, H.E.; Kaplancıklı Z.A. New thiazoline-tetralin derivatives and biologi-cal activity evaluation. Molecules, 2018, 23(1), 135.
[http://dx.doi.org/10.3390/molecules23010135] [PMID: 29320423]

Nagireddy, P.K.R.; Kommalapati, V.K.; Siva Krishna, V.; Sriram, D.; Tangutur, A.D.; Kantevari, S. Imidazo[2,1-b]thiazole-coupled natural noscapine derivatives as anticancer agents. ACS Omega, 2019, 4(21), 19382-19398.
[http://dx.doi.org/10.1021/acsomega.9b02789] [PMID: 31763563]

Aouad, M.R.; Soliman, M.A.; Alharbi, M.O.; Bardaweel, S.K.; Sahu, P.K.; Ali, A.A.; Messali, M.; Rezki, N.; Al-Soud, Y.A. Design, syn-thesis and anticancer screening of novel benzothiazole-piperazine-1,2,3-triazole hybrids. Molecules, 2018, 23(11), 2788.
[http://dx.doi.org/10.3390/molecules23112788] [PMID: 30373247]

Gomha, S.M.; Ahmed, S.A.; Abdelhamid, A.O. Synthesis and cytotoxicity evaluation of some novel thiazoles, thiadiazoles, and pyri-do[2,3-d][1,2,4]triazolo[4,3-a]pyrimidin-5(1H)-ones incorporating triazole moiety. Molecules, 2015, 20(1), 1357-1376.
[http://dx.doi.org/10.3390/molecules20011357] [PMID: 25594346]

Madadi, N.R.; Penthala, N.R.; Howk, K.; Ketkar, A.; Eoff, R.L.; Borrelli, M.J.; Crooks, P.A.; Sciences, M.; Rock, L.; Rock, L. Synthesis and biological evaluation of novel 4,5-disubstituted 2H-1,2,3-triazoles as cis-constrained analogues of combretastatin A-4. Eur. J. Med. Chem., 2015, 103, 123-132.
[http://dx.doi.org/10.1016/j.ejmech.2015.08.041] [PMID: 26352674]

Huang, X.; Shen, Q.K.; Zhang, H.J.; Li, J.L.; Tian, Y.S.; Quan, Z.S. Design and synthesis of novel dehydroepiandrosterone analogues as potent antiproliferative agents. Molecules, 2018, 23(9), 2243.
[http://dx.doi.org/10.3390/molecules23092243] [PMID: 30177642]

Alam, M.M.; Almalki, A.S.A.; Neamatallah, T.; Ali, N.M.; Malebari, A.M.; Nazreen, S. Synthesis of new 1, 3, 4-oxadiazole-incorporated 1, 2, 3-triazole moieties as potential anticancer agents targeting thymidylate synthase and their docking studies. Pharmaceuticals (Basel), 2020, 13(11), 390.
[http://dx.doi.org/10.3390/ph13110390] [PMID: 33202652]

Ye, W.; Yao, Q.; Yu, S.; Gong, P.; Qin, M. Synthesis and antitumor activity of triazole-containing sorafenib Analogs. Molecules, 2017, 22(10), 1759.
[http://dx.doi.org/10.3390/molecules22101759] [PMID: 29064424]

Bębenek, E.; Jastrzębska, M.; Kadela-Tomanek, M.; Chrobak, E.; Orzechowska, B.; Zwolińska, K.; Latocha, M.; Mertas, A.; Czuba, Z.; Boryczka, S. Novel triazole hybrids of betulin: Synthesis and biological activity profile. Molecules, 2017, 22(11), 1876.
[http://dx.doi.org/10.3390/molecules22111876] [PMID: 29104263]

Zhu, X.P.; Lin, G.S.; Duan, W.G.; Li, Q.M.; Li, F.Y.; Lu, S.Z. Synthesis and antiproliferative evaluation of novel longifolene-derived tetra-lone derivatives bearing 1,2,4-triazole moiety. Molecules, 2020, 25(4), 986.
[http://dx.doi.org/10.3390/molecules25040986] [PMID: 32098438]

Boraei, A.T.A.; Ghabbour, H.A.; Gomaa, M.S.; El Ashry, E.S.H.; Barakat, A. Synthesis and anti-proliferative assessment of triazolo-thiadiazepine and triazolo-thiadiazine Scaffolds. Molecules, 2019, 24(24), 4471.
[http://dx.doi.org/10.3390/molecules24244471] [PMID: 31817609]

Kumar, S.; Saha, S.T.; Gu, L.; Palma, G.; Perumal, S.; Singh-Pillay, A.; Singh, P.; Anand, A.; Kaur, M.; Kumar, V. 1H-1,2,3-triazole teth-ered nitroimidazole-isatin conjugates: Synthesis, docking, and anti-proliferative evaluation against breast cancer. ACS Omega, 2018, 3(9), 12106-12113.
[http://dx.doi.org/10.1021/acsomega.8b01513] [PMID: 30320289]

Banerji, B.; Chandrasekhar, K.; Sreenath, K.; Roy, S.; Nag, S.; Saha, K.D. Synthesis of triazole-substituted quinazoline hybrids for anti-cancer activity and a lead compound as the EGFR blocker and ROS inducer agent. ACS Omega, 2018, 3(11), 16134-16142.
[http://dx.doi.org/10.1021/acsomega.8b01960] [PMID: 30556027]

Al Sheikh Ali, A.; Khan, D.; Naqvi, A.; Al-Blewi, F.F.; Rezki, N.; Aouad, M.R.; Hagar, M. Design, synthesis, molecular modeling, anti-cancer studies, and density functional theory calculations of 4-(1,2,4-triazol-3-ylsulfanylmethyl)-1,2,3-triazole derivatives. ACS Omega, 2020, 6(1), 301-316.
[http://dx.doi.org/10.1021/acsomega.0c04595] [PMID: 33458482]

Gu, L.; Wang, P.; Zhong, Q.; Deng, Y.; Xie, J.; Liu, F.; Xiao, F.; Zheng, S.; Chen, Y.; Wang, G.; He, L. Copper salt-catalyzed formation of a novel series of triazole-spirodienone conjugates with potent anticancer activity. RSC Advances, 2017, 7(16), 9412-9416.
[http://dx.doi.org/10.1039/C6RA24764D] [PMID: 30740218]

Zi, C.T.; Liu, Z.H.; Li, G.T.; Li, Y.; Zhou, J.; Ding, Z.T.; Hu, J.M.; Jiang, Z.H. Design, synthesis, and cytotoxicity of perbutyrylated glyco-sides of 4β-triazolopodophyllotoxin derivatives. Molecules, 2015, 20(2), 3255-3280.
[http://dx.doi.org/10.3390/molecules20023255] [PMID: 25690288]

Zi, C.T.; Li, G.T.; Li, Y.; Zhou, J.; Ding, Z.T.; Jiang, Z.H.; Hu, J.M. Synthesis and anticancer activity of 4β-triazole-podophyllotoxin gly-cosides. Nat. Prod. Bioprospect., 2015, 5(2), 83-90.
[http://dx.doi.org/10.1007/s13659-015-0057-3] [PMID: 25869591]

Harej, A.; Macan, A.M. Stepanić V.; Klobučar, M.; Pavelić K.; Pavelić S.K.; Raić-Malić S. The antioxidant and antiproliferative activi-ties of 1,2,3-triazolyl-L-ascorbic acid derivatives. Int. J. Mol. Sci., 2019, 20(19), 4735.
[http://dx.doi.org/10.3390/ijms20194735] [PMID: 31554245]

Singh, A.; Saha, S.T.; Perumal, S.; Kaur, M.; Kumar, V. Azide-Alkyne Cycloaddition En Route to 1H-1,2,3-triazole-tethered isatin-ferrocene, ferrocenylmethoxy-isatin, and isatin-ferrocenylchalcone conjugates: Synthesis and antiproliferative evaluation. ACS Omega, 2018, 3(1), 1263-1268.
[http://dx.doi.org/10.1021/acsomega.7b01755] [PMID: 30023800]

Malarz, K.; Mrozek-Wilczkiewicz, A.; Serda, M.; Rejmund, M.; Polanski, J.; Musiol, R. The role of oxidative stress in activity of anti-cancer thiosemicarbazones. Oncotarget, 2018, 9(25), 17689-17710.
[http://dx.doi.org/10.18632/oncotarget.24844] [PMID: 29707141]

de Almeida, S.M.V.; Lafayette, E.A.; da Silva, L.P.B.G.; Amorim, C.A.; de Oliveira, T.B.; Ruiz, A.L.; de Carvalho, J.E.; de Moura, R.O.; Beltrão, E.I. de Lima, Mdo.C.; de Carvalho Júnior, L.B. Synthesis, DNA binding, and antiproliferative activity of novel acridine-thiosemicarbazone derivatives. Int. J. Mol. Sci., 2015, 16(6), 13023-13042.
[http://dx.doi.org/10.3390/ijms160613023] [PMID: 26068233]

Pham, V.H.; Phan, T.P.D.; Phan, D.C.; Vu, B.D. Synthesis and bioactivity of thiosemicarbazones containing adamantane skeletons. Molecules, 2020, 25(2), 324.
[http://dx.doi.org/10.3390/molecules25020324] [PMID: 31941142]

Ma, L.; Wang, H.; Wang, J.; Liu, L.; Zhang, S.; Bu, M. Novel steroidal 5α8α-endoperoxide derivatives with semicarba-zone/thiosemicarbazone side-chain as apoptotic inducers through an intrinsic apoptosis pathway: Design, synthesis and biological studies. Molecules, 2020, 25(5), 1209.
[http://dx.doi.org/10.3390/molecules25051209]

Sestak, V.; Stariat, J.; Cermanova, J.; Potuckova, E.; Chladek, J.; Roh, J.; Bures, J.; Jansova, H.; Prusa, P.; Sterba, M.; Micuda, S.; Simunek, T.; Kalinowski, D.S.; Richardson, D.R.; Kovarikova, P. Novel and potent anti-tumor and anti-metastatic di-2-pyridylketone thiosemicarba-zones demonstrate marked differences in pharmacology between the first and second generation lead agents. Oncotarget, 2015, 6(40), 42411-42428.
[http://dx.doi.org/10.18632/oncotarget.6389] [PMID: 26623727]

Gomha, S.M.; Abdelhady, H.A.; Hassain, D.Z.H.; Abdelmonsef, A.H.; El-Naggar, M.; Elaasser, M.M.; Mahmoud, H.K. Thiazole-based thiosemicarbazones: Synthesis, cytotoxicity evaluation and molecular docking study. Drug Des. Devel. Ther., 2021, 15, 659-677.
[http://dx.doi.org/10.2147/DDDT.S291579] [PMID: 33633443]

Bharathi, S.; Mahendiran, D.; Kumar, R.S.; Choi, H.J.; Gajendiran, M.; Kim, K.; Rahiman, A.K. Silver(I) metallodrugs of thiosemicarba-zones and naproxen: Biocompatibility, in vitro anti-proliferative activity and in silico interaction studies with EGFR, VEGFR2 and LOX re-ceptors. Toxicol. Res. (Camb.), 2020, 9(1), 28-44.
[http://dx.doi.org/10.1093/toxres/tfaa001] [PMID: 32440336]

Hernández, W.; Paz, J.; Carrasco, F.; Vaisberg, A.; Spodine, E.; Manzur, J.; Hennig, L.; Sieler, J.; Blaurock, S.; Beyer, L. Synthesis and characterization of new palladium(II) thiosemicarbazone complexes and their cytotoxic activity against various human tumor cell lines. Bioinorg. Chem. Appl., 2013, 2013524701
[http://dx.doi.org/10.1155/2013/524701] [PMID: 24391528]

Zeglis, B.M.; Divilov, V.; Lewis, J.S. Role of metalation in the topoisomerase IIα inhibition and antiproliferation activity of a series of α-heterocyclic-N4-substituted thiosemicarbazones and their Cu(II) complexes. J. Med. Chem., 2011, 54(7), 2391-2398.
[http://dx.doi.org/10.1021/jm101532u] [PMID: 21391686]

Leeson, P.D.; Springthorpe, B. The influence of drug-like concepts on decision-making in medicinal chemistry. Nat. Rev. Drug Discov., 2007, 6(11), 881-890.
[http://dx.doi.org/10.1038/nrd2445] [PMID: 17971784]

Curatolo, W. Physical chemical properties of oral drug candidates in the Discovery and exploratory development settings. Pharm. Sci. Technol. Today, 1998, 1, 387-393.
[http://dx.doi.org/10.1016/S1461-5347(98)00097-2]

Wenlock, M.C.; Barton, P. In silico physicochemical parameter predictions. Mol. Pharm., 2013, 10(4), 1224-1235.
[http://dx.doi.org/10.1021/mp300537k] [PMID: 23305561]

Tetko, I.V. Computing chemistry on the web. Drug Discov. Today, 2005, 10(22), 1497-1500.
[http://dx.doi.org/10.1016/S1359-6446(05)03584-1] [PMID: 16257371]

Lipinski, C.A.; Lombardo, F.; Dominy, B.W.; Feeney, P.J. Experimental and computational approaches to estimate solubility and permea-bility in drug discovery and developmental settings. Adv. Drug Deliv. Rev., 1997, 23, 3-25.
[http://dx.doi.org/10.1016/S0169-409X(96)00423-1]

Lipinski, C.A.; Lombardo, F.; Dominy, B.W.; Feeney, P.J. Experimental and computational approaches to estimate solubility and permea-bility in drug discovery and development settings. Adv. Drug Deliv. Rev., 2001, 46(1-3), 3-26.
[http://dx.doi.org/10.1016/S0169-409X(00)00129-0] [PMID: 11259830]

Zuniga, E.S.; Early, J.; Parish, T. The future for early-stage tuberculosis drug discovery. Future Microbiol., 2015, 10(2), 217-229.
[http://dx.doi.org/10.2217/fmb.14.125] [PMID: 25689534]

Manjunatha, U.H.; Smith, P.W. Perspective: Challenges and opportunities in TB drug discovery from phenotypic screening. Bioorg. Med. Chem., 2015, 23(16), 5087-5097.
[http://dx.doi.org/10.1016/j.bmc.2014.12.031] [PMID: 25577708]

Waring, M.J. Lipophilicity in drug discovery. Expert Opin. Drug Discov., 2010, 5(3), 235-248.
[http://dx.doi.org/10.1517/17460441003605098] [PMID: 22823020]

Chen, M.; Borlak, J.; Tong, W. High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury. Hepatology, 2013, 58(1), 388-396.
[http://dx.doi.org/10.1002/hep.26208] [PMID: 23258593]

Tarcsay, Á. Keserű G.M. Contributions of molecular properties to drug promiscuity. J. Med. Chem., 2013, 56(5), 1789-1795.
[http://dx.doi.org/10.1021/jm301514n] [PMID: 23356819]